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1. Introduction 
1.1 An overview on the role of catecholamines: Basic physiology and pharmacology 
Tremendous advances in the knowledge of catecholamines occurred in the last century, 
namely the discovery of their chemical structure, the notion of adrenoceptors by Ahlquist or 
the characterization of (at least in part) their transduction pathways. General concepts 
related to catecholamines, namely their synthesis, storage, reuptake, release, action 
termination, the adrenergic receptors, and their transduction pathways will be approached 
in this chapter. Additionally, the levels of catecholamines and metabolites found in human 
plasma and urine will be briefly addressed. Special focus will be given to adrenaline (ADR) 
and noradrenaline (NA) since they are the main actors of the human adaptation to the 
environment. ADR and NA are responsible for the cross talk between the sympathetic 
nervous system (and central nervous system) and adrenal medulla. 
2. Historic introduction and background 
In 1856, Vulpian applied a solution of ferric chloride to slices of adrenal glands and noticed 
that the medulla stained green while the cortex did not. He also observed that the same 
reaction occurred in samples of venous blood leaving the adrenal, but not in the arterial 
blood entering the gland. To account for these observations, Vulpian assumed that the 
medulla synthesized a substance that was released into the circulation (Vulpian, 1856). In 
1895, Oliver and Schäfer demonstrated the first pharmacological action of catecholamines 
when they showed that the administration of extracts of adrenal gland led to the rise of 
arterial blood pressure (Oliver and Schäfer, 1895).  
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In 1897, Abel and Crawford obtained a compound that they called “epinephrin” (Abel and 
Crawford, 1897). The mono-benzoyl derivative isolated was however less active than the 
crude extracts, so the quest for the bioactive compound continued. In 1901, Takamine, an 
industrial chemist, isolated the active principle, then named “adrenalin” (Takamine, 1902) 
(Figure 1). Takamine’s notation was adopted by the Europeans but not by North American 
researchers, thus resulting in the different nomenclature of both sides of the Atlantic Ocean. 
 
Fig. 1. Chemical structures of biogenic catecholamines. 
Catecholamines soon became the centre of one of the most endurable and passionate 
scientific discussions, with tremendous breakthroughs that crossed the twentieth century. 
When reporting to catecholamines, under the general heading are NA (also known as 
norepinephrine), the principal transmitter of sympathetic postganglionic fibres and certain 
tracts of the central nervous system; dopamine, a known transmitter of the mammalian 
nigrostriatal, mesocortical, and mesolimbic neuronal pathways; and ADR (also known as 
epinephrine), the major hormone of the adrenal medulla. Collectively, these three amines 
are called biogenic catecholamines (Westfall and Westfall, 2006) and are involved in the 
regulation of motor coordination, learning and memory, sleep-wake cycle regulation, as 
well as in endocrine and visceral functions (Wevers et al., 1999).  
3. Structure and main location of catecholamine-releasing sites 
NA, ADR, and dopamine are known as catecholamines, as they contain a catechol moiety, 
an amine side-chain and they are all derived from the amino acid tyrosine (Westfall and 
Westfall, 2006, Baynes and Dominiczak, 2007, Rang et al., 2007) (Figure 1). Catecholamines 
share with 5-hydroxytryptamine (5-HT; serotonin) the amino side chain and altogether are 
known as biogenic amines. Similar compounds, like isoproterenol (previously isoprenaline), 
a synthetic derivative of NA, are catecholamines but not biogenic amines (Rang et al., 
2007). 
Although many before postulated it, von Euler was the first to show that NA was the main 
neurotransmitter in the sympathetic nervous system (von Euler, 1946). Sympathetic nerves 
arise from the spinal cord and run to the ganglia situated close to it; from those ganglia the 
postganglionic noradrenergic nerves run to the target tissues. Stimulation of the sympathetic 
nerves is inseparable from the “fight or flight” response, which results in the secretion of 
corticosteroids by the adrenal cortex and the release of ADR and NA by the adrenal medulla 
and sympathetic nerves (Wang et al., 1999, Baynes and Dominiczak, 2007). Together with 
ADR and corticosteroids, NA helps to coordinate different body part responses for 
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adaptation to a stressful situation. The main function of NA is to orchestrate the response of 
the body to stress culminating in increased heart rate and blood pressure, and enhanced 
energy mobilization and neural reflexes (Wang et al., 1999, Westfall and Westfall, 2006).  
NA is a neurotransmitter found in the peripheral and central nervous system, where it 
regulates a numerous assortment of physiological processes that include mood, arousal, 
learning and memory, blood flow, and metabolism (Axelrod and Kopin, 1969, Xu et al., 
2000, Nolte, 2009). As a central nervous system neurotransmitter, NA is synthesized 
primarily in the brainstem nuclei locus ceruleus and subceruleus, which project rostrally to 
virtually every region of the midbrain and forebrain, dorsoventrally to the cerebellum, and 
caudally to lumbar segments of the spinal cord (Wang et al., 1999, Westfall and Westfall, 
2006, Nolte, 2009). Additionally, the A1, C1, A2, C2, C3, A4, A5, and A7 noradrenergic cell 
groups also provide projections into the brain. Noradrenergic projections are identified in 
virtually every region of the midbrain, forebrain and cerebellum (Nolte, 2009). In the 
peripheral nervous system, NA is synthesized and released from sympathetic neurons 
connected to a wide variety of endocrine organs and other tissues (Axelrod and Kopin, 1969, 
Wang et al., 1999, Nolte, 2009). This extensive projection pattern throughout the neuroaxis 
defines NA as a general regulator of neurotransmission. NA is directly involved in mood 
stabilization, sleep regulation, aggression and in the general degree of alertness and arousal. 
NA is also involved in the central control over the endocrine and autonomic nervous 
systems (Wang et al., 1999, Westfall and Westfall, 2006, Nolte, 2009). 
Although generally treated only as an endocrine hormone, ADR also acts as a 
neurotransmitter released in central and peripheral adrenergic neurons (Loewi, 1936, Jarrott, 
1970, Fuller, 1982). Indeed, Loewi demonstrated the presence of an “acceleranstoff” released 
from sympathetic neurons that innervated the heart of frogs (Loewi, 1921), later found to be 
ADR (Loewi, 1936, Azuma et al., 1965, Norberg and McIsaac, 1967). The presence of ADR in 
the mammalian central nervous system was recognized both in biochemical and 
neuroanatomical studies (Lew et al., 1977, Pendleton et al., 1978, Moore and Bloom, 1979, 
Armstrong et al., 1982, Goodchild et al., 1984). The existence and function of only ADR-
synthesizing neurons are not without controversy (Mefford, 1987). The confirmation of 
specific neurons in the central nervous system that contain ADR occurred after the 
development of sensitive enzymatic assays and immunocytochemical staining techniques 
for phenylethanolamine N-methyltransferase (PNMT), the enzyme responsible for the 
synthesis of ADR (Axelrod, 1962, Lew et al., 1977, Pendleton et al., 1978). Subsequently, 
neuroanatomical studies using antibodies against PNMT showed the presence of ADR-
synthesizing neurons in the C1, C2, and C3 cell groups of the medulla oblongata and the 
nucleus tractus solitarii in multiple species (Goodchild et al., 1984, Carlton et al., 1987, Carlton 
et al., 1991), including humans (Burke et al., 1986, Halliday et al., 1988, Kitahama et al., 
1988). Many other studies have shown the existence of adrenergic neurons in the medullar 
reticular formation that make restricted connections to a few pontine and diencephalic 
nuclei, eventually coursing as far rostrally as the paraventricular nucleus of the dorsal 
midline thalamus (Armstrong et al., 1982, Chamba and Renaud, 1983, Goodchild et al., 1984, 
Ross et al., 1984b, Stolk et al., 1984, Bloom, 2006). It is recognized nowadays that ADR 
synthesizing neurons are involved in cardiovascular homeostasis in both physiological and 
pathophysiological conditions (Moore and Bloom, 1979, Goodchild et al., 1984, Reis et al., 
1984, Ross et al., 1984a, Johansson et al., 1997). 
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In adults, ADR accounts for approximately 80% of adrenal medulla catecholamine content, 
with NA making up most of the remaining (von Euler, 1972). Although the adrenal gland 
and neurons are the most prominent sites of PNMT expression in the adult mammal, this 
enzyme has also been detected in the retina (Hadjiconstantinou et al., 1983, Foster et al., 
1985, Park et al., 1986), spleen (Pendleton et al., 1978), lungs (Pendleton et al., 1978, Kennedy 
et al., 1990), and heart (Axelrod, 1962, Pendleton et al., 1978, Culman et al., 1987, Torda et al., 
1987, Kennedy and Ziegler, 1991). ADR triggers coordinated metabolic and physiological 
processes in response to stress (Westfall and Westfall, 2006). ADR is more active than NA in 
the heart and lungs, it causes redirection of blood from the skin to skeletal muscle and it has 
important stimulatory effects in the glycogen metabolism of the liver (Westfall and Westfall, 
2006, Baynes and Dominiczak, 2007, Rang et al., 2007).  
Dopamine (3,4-dihydroxyphenylethylamine) is the immediate metabolic precursor of NA 
and ADR (Figure 2). Although dopamine originally was regarded only as a precursor of  
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Fig. 2. The synthesis of catecholamines. Tyrosine hydroxylase hydroxylates tyrosine and 
forms L-3,4-dihydroxyphenylalanine (L-dopa). L-dopa is decarboxylated to form dopamine 
through the catalysis of dopa decarboxylase. Dopamine ǃ-hydroxylase ǃ-hydroxylates 
dopamine to yield noradrenaline. Noradrenaline is N-methylated by phenylethanolamine 
N-methyltransferase to form adrenaline in adrenergic neurons and other adrenaline 
producing cells. 
www.intechopen.com
 
Adrenaline and Noradrenaline: Partners and Actors in the Same Play 5 
NA, studies on distinct central nervous system regions revealed that the distribution of 
dopamine and NA neurons is markedly different (Bloom, 2006). More than half of the 
central nervous system catecholamine content is dopamine and extremely large amounts 
are found in the basal ganglia (especially the caudate nucleus), the nucleus accumbens, the 
olfactory tubercle, the central nucleus of the amygdala, the median eminence, and 
restricted fields of the frontal cortex (Bloom, 2006). Of the wide variety of connections, the 
greatest attention has been given to the long projections between the major dopamine-
containing nuclei located at the substantia nigra and ventral tegmentum and their targets 
in the striatum. In addition, two important central dopaminergic systems are functionally 
located outside the blood-brain barrier: in the chemoceptor trigger zone and in the 
anterior pituitary. In the periphery, dopamine is synthesized in epithelial cells of the 
proximal tubules and it is thought to exert local diuretic and natriuretic effects in the 
kidneys (Esler et al., 1990, Bloom, 2006). Likewise, dopamine receptors are found in the 
proximal gastrointestinal tract where their activation delays gastric emptying. 
Dopaminergic receptors are also present in renal, mesenteric, coronary and intracerebral 
arteries (Bloom, 2006). At the cellular level, the actions of dopamine depend on the 
expression of the different receptor subtypes and the contingent actions of other 
transmitters to the same target neurons (Bloom, 2006). This catecholamine will not be 
deeply addressed in the present work, except in specific circumstances where it can be of 
relevance to the theme.  
4. Synthesis of catecholamines 
The mechanisms of catecholamine synthesis, storage, release, and binding have been mainly 
studied in sympathetically innervated organs and in the adrenal medulla (Westfall and 
Westfall, 2006). 
The steps that occur in the synthesis of dopamine, NA, and ADR are shown in Figure 2. In 
the cytoplasm, tyrosine is sequentially 3-hydroxylated by tyrosine hydroxylase to form L-
3,4-dihydroxyphenylalanine, which is then decarboxylated to form dopamine by L-3,4-
dihydroxyphenylalanine decarboxylase (also known as aromatic L-amino acid 
decarboxylase) (Axelrod, 1962). Dopamine ǃ-hydroxylase ǃ-hydroxylates dopamine to yield 
NA, which is N-methylated by PNMT to form ADR, in adrenergic neurons and other ADR 
producing cells (Rang et al., 2007). The enzymes involved in this synthesis have been 
identified, cloned, and characterized (Nagatsu, 1991).  
In adrenergic neurons, the enzymes that participate in NA formation are synthesized in the 
cell bodies of neurons and are then transported along the axon to the terminals. In the 
course of NA synthesis, both the hydroxylation of tyrosine to L-3,4-dihydroxyphenylalanine 
and the decarboxylation of L-3,4-dihydroxyphenylalanine to dopamine take place in the 
cytoplasm. About half of the dopamine formed in the cytoplasm is then actively transported 
into the dopamine ǃ-hydroxylase-containing storage vesicles, where it is converted to NA. 
The remainder escapes active transport to the vesicles and is deaminated to 3,4-
dihydroxyphenylacetic acid and subsequently O-methylated to homovanillic acid (HVA) 
(Westfall and Westfall, 2006). In ADR-producing cells, the NA formed in the vesicles leaves 
them and it is methylated in the cytoplasm by PNMT to yield ADR. ADR then re-enters the 
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vesicles, where it is stored and concentrated for subsequent release (Masson et al., 1999, 
Westfall and Westfall, 2006). 
The hydroxylation of tyrosine by tyrosine hydroxylase is generally regarded as the rate-
limiting step in the biosynthesis of catecholamines (Zigmond et al., 1989). This enzyme is 
activated after stimulation of sympathetic nerves or adrenal medulla and is tightly 
regulated. In fact, tyrosine hydroxylase is substrate for protein kinase A (PKA), protein 
kinase C (PKC) and calcium/calmodulin-dependent protein kinase II (CaMKII). The kinase-
catalysed phosphorylation results in the increase of tyrosine hydroxylase activity (Zigmond 
et al., 1989, Daubner et al., 1992). This is an important acute mechanism to increase the 
synthesis of catecholamines in response to elevated nerve stimulation. Likewise, tyrosine 
hydroxylase activity is subject to a feedback inhibition by catechol compounds, which 
allosterically modulate the activity of the enzyme (Kumer and Vrana, 1996). On the other 
hand, the expression of tyrosine hydroxylase can be increased at multiple levels, including 
transcription, ribonucleic acid (RNA) processing, regulation of RNA stability, translation, 
and enzyme stability (Kumer and Vrana, 1996). 
Tyrosine hydroxylase deficiency has been reported in humans and is characterized by 
generalized rigidity, hypokinesia, among other symptoms. Low cerebrospinal fluid levels of 
NA and dopamine metabolites, like HVA and 3-methoxy-4-hydroxy-phenylethylene glycol 
are observed in humans with tyrosine hydroxylase deficiency (Wevers et al., 1999, Carson 
and Robertson, 2002). The tyrosine hydroxylase knockout is unviable in mice as they die in 
the embryonic stage, presumably because catecholamine loss results in altered cardiac 
function (Zhou et al., 1995). Interestingly, residual levels of dopamine are present in these 
embryonic mice, suggesting that tyrosinase may be an alternate way to form 
catecholamines. However, the amount of tyrosinase-derived catecholamines is clearly not 
sufficient for the survival of the animals (Carson and Robertson, 2002).  
Dopamine ǃ-hydroxylase deficiency in humans is characterized by orthostatic hypotension, 
ptosis of the eyelids, retrograde ejaculation, and elevated plasma levels of dopamine 
(Westfall and Westfall, 2006). In the case of dopamine ǃ-hydroxylase-deficient mice, there is 
about 90% embryonic mortality (Carson and Robertson, 2002).  
At rest, the basal cardiovascular function in PNMT knockout mice showed little change. In 
fact, ADR was found indispensable for normal blood pressure and cardiac filling responses 
to stress but it was not required in tachycardia during stress or in normal cardiovascular 
function at rest (Bao et al., 2007, Sun et al., 2008). Furthermore, glucocorticoids levels are 
very important in the expression of PMNT and thus in the rate of ADR synthesis. 
Glucocorticoids are very relevant in the size of the stores of ADR available for release in the 
brain (Moore and Phillipson, 1975b, a), adrenal medulla (Kelner and Pollard, 1985, 
Stachowiak et al., 1988, Wan and Livett, 1989, Ross et al., 1990, Betito et al., 1992, Wong et al., 
1992), heart (Kennedy and Ziegler, 1991, Krizanova et al., 2001, Kvetnansky et al., 2004) or 
lungs (Kennedy et al., 1993). The activities of both tyrosine hydroxylase and dopamine ǃ-
hydroxylase are also increased in the adrenal medulla under the influence of glucocorticoids 
(Carroll et al., 1991). Thus, any stress that persists sufficiently to evoke an enhanced 
secretion of corticotrophin mobilizes the appropriate hormones of both the adrenal cortex 
(predominantly cortisol in humans) and adrenal medulla. 
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5. Intracellular storage of catecholamines 
Neurotransmission depends mainly on the regulated release of chemical transmitter 
molecules. That release requires the packing of these substances into the specialized 
secretory vesicles of neurons and neuroendocrine cells. The neuronal content of 
catecholamines is confined to vesicles, while in adrenal medulla, catecholamines are stored 
in chromaffin granules. These vesicles contain extremely high concentrations of 
catecholamines (approximately 21% dry weight), ascorbic acid, and adenosine-5'-
triphosphate (ATP), as well as chromogranins, dopamine ǃ-hydroxylase, and peptides, 
including enkephalin and neuropeptide Y. Two types of storage vesicles are actually found 
in sympathetic nerve terminals: large dense-core vesicles equivalent to the chromaffin 
granules and small dense-core vesicles containing NA, ATP, and membrane-bound 
dopamine ǃ-hydroxylase (Bloom, 2006). The enhanced activity of the sympathetic nervous 
system is accompanied by increase of both dopamine ǃ-hydroxylase and chromogranins in 
circulation, thus supporting the argument that the process of release, following the 
adrenergic nerve stimulation, involves exocytosis (Westfall and Westfall, 2006). 
The storage process decreases the intraneuronal metabolism of the transmitters and their 
leak out of the cell. This allows to control the concentration gradient across the plasma 
membrane and to prevent possible toxic effects that could occur when the cytoplasmic 
concentration of catecholamines exceeds critical levels (Schuldiner, 1994, Masson et al., 
1999). The storage process is mediated by specific vesicular transporters (Schuldiner et al., 
1978, Erickson et al., 1992, Schuldiner, 1994, Masson et al., 1999). In mammals, there are two 
closely related vesicular monoamine transporter (VMAT) isoforms that are named VMAT-1 
and VMAT-2. VMAT-1 is primarily present in endocrine and paracrine cells, while VMAT-2 
is the predominant monoamine transporter in the nervous system (Masson et al., 1999). 
VMAT-2 is mainly expressed in dense core vesicles of axon terminals (Figure 3) (Nirenberg 
et al., 1997). 
Monoamine vesicular transporters are relatively promiscuous when concerning to their 
substrates. They transport dopamine, NA, ADR, and 5-HT but they differ in substrate 
preference and affinity. Several vesicular transport complementary deoxyribonucleic acid 
(cDNA) have been cloned; these complementary DNAs reveal open reading frames 
predictive of proteins with 12 transmembrane domains (Masson et al., 1999). Reserpine 
inhibits the monoamine vesicular transport and ultimately leads to the depletion of 
catecholamines inside the nerve endings (von Euler, 1972, Masson et al., 1999). 
The vesicular transport is driven by pH and potential gradients which are  established by 
ATP-dependent proton pumps. The ATP-driven H+ pump, on one hand, acidifies the 
vesicular lumen (ΔpH) and, on the other hand, generates a potential gradient 
(ΔΨ)(Schuldiner et al., 1978, Johnson and Scarpa, 1979). For every molecule taken in, two 
internal H+ ions are extruded by VMAT-2 by an antiport process (Masson et al., 1999). 
Therefore, the intravesicular concentration of monoamines depends upon ΔΨ and ΔpH 
(Njus et al., 1986, Rottenberg, 1986, Johnson, 1988, Schuldiner, 1994, Masson et al., 1999). In 
addition, the monoamine uptake is modulated by vesicle-associated heterotrimeric guanine 
nucleotide binding regulatory proteins (G proteins), Gǂo2 and Gǂq (Ahnert-Hilger et al., 1998, 
Holtje et al., 2000, Holtje et al., 2003). G proteins control transmitter storage: the  
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Fig. 3. Catecholamines in axon terminals. The axon terminal has neurotransmitter storage 
vesicles with catecholamines and cotransmitters. The vesicular monoamine transporter 
(VMAT) is responsible for the transport of catecholamines to the storage vesicles, maintaining 
their cytosolic concentration low. After catecholamine release to the synaptic cleft, 
catecholamines are reuptaken to the presynaptic terminal by noradrenaline transporter (NET), 
and/or taken to extraneuronal cells by the extraneuronal transporters. The most important 
extraneuronal transporter for catecholamines is extraneuronal monoamine transporter (EMT). 
Catecholamines are metabolized by intracellular enzymes. Monoamine oxidase (MAO) is 
located in the outer membrane of mitochondria in neurons and in extraneuronal cells. 
Catechol-O-methyl transferase (COMT) is located at extraneuronal cells. Both enzymes 
(COMT and MAO) are the main responsible for the metabolism of catecholamines. The 
enzymatic process leads to the formation of several metabolites. To exert their actions, the 
catecholamines and other neurotransmitters in the synaptic cleft bind to different pre- and 
postsynaptic receptors. Such binding leads to alterations in the postsynaptic cell and activation 
of intracellular pathways through G proteins. In presynaptic neurons, catecholamines bind to 
autoreceptors and activate feed-back responses that change their own release. 
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monoamines stored inside the vesicles represent the upstream signal that mediates the 
inhibition to further uptake through G proteins. In fact, biogenic amines, with the exception 
of ADR, lead to G protein-mediated inhibition; VMATs have a receptor-like area in their 
first luminal loop that senses the intravesicular concentration of monoamines (Brunk et al., 
2006). 
6. Release of catecholamines 
Depolarization of the axonal terminal triggers the release of catecholamines into the cleft. 
The content of the vesicles, including enzymes, neurotransmitters, and hormones, is 
discharged to the exterior through a process termed exocytosis (Figure 3). Triggered 
exocytosis is the most common cellular mechanism for the release of polar molecules and it 
involves several mechanisms that include vesicle docking, priming, and fusion. It can be 
regulated or constitutive. In synaptic transmission, a synchronized mechanism provides the 
cells with a way for precisely timed release of molecules into the extracellular space (Pocock 
and Richards, 2006). The full sequence of steps by which the nerve impulse affects the 
release of transmitters from sympathetic neurons is not yet fully understood. 
In the adrenal medulla, the triggering event to exocytosis is the release of acetylcholine by 
the preganglionic fibres; that acetylcholine binds to nicotinic receptors on chromaffin cells 
which produce a localized depolarization. In most types of cells, regulated exocytosis is 
triggered by the increase in cytosolic free calcium (Ca2+) (Meir et al., 1999, Pocock and 
Richards, 2006). This cytosolic Ca2+ enters the cells from the extracellular medium, through 
the voltage-gated Ca2+ channels. The voltage-gated Ca2+ channels open following 
depolarization of the plasma membrane, making the Ca2+ able to diffuse into the cell down 
its electrochemical gradient. Ca2+ is also mobilized from intracellular stores (mainly the 
endoplasmic reticulum). As result, the intracellular free Ca2+ increases and it triggers the 
fusion of secretory vesicles with the plasma membrane. Ca2+-triggered secretion involves the 
interaction of highly conserved molecular scaffolding proteins and leads to the docking of 
the vesicles (Aunis, 1998, Meir et al., 1999). As fusion continues, a pore is formed and it 
connects the extracellular space with the interior of the vesicle thus providing a pathway for 
vesicle content to diffuse into the extracellular space (Pocock and Richards, 2006) (Figure 3).  
Other aspects concerning modulation of catecholamine transmission or secretion will be 
better addressed in a subsequent section where adrenoceptors and their role in augmenting 
or diminishing the synaptic release will be focused. 
7. Neuronal transporters involved in catecholamine reuptake 
Synaptic transmission involves the regulated release of transmitters into the synaptic cleft, 
where they interact with receptors that subsequently transduce the information. The 
removal of catecholamines from the cleft usually occurs by uptake either back to the 
presynaptic terminal or into the postsynaptic cell (Iversen et al., 1967, Axelrod and Kopin, 
1969). A number of high-affinity transporters have been identified, namely for dopamine, 
NA, 5-HT, and several aminoacid transmitters (Masson et al., 1999). These transporters are 
members of an extensive family that share common structural motifs, particularly the 
putative 12-transmembrane helices (Bönisch and Brüss, 2006). The transporters show a 
similar configuration of intracellular and extracellular loops or related regions that contain 
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phosphorylation and glycosylation sites and intracellular located amino- and carboxyl-
terminal residues (Eisenhofer, 2001). Dopamine is cleared by dopamine transporter whilst 
NA and ADR are cleared by NA transporter (NET) (Figure 3) (Trendelenburg, 1988, 
Apparsundaram et al., 1997, Eisenhofer, 2001). These plasma membrane transporters have 
higher substrate specificity than vesicular transporters and may be viewed as targets 
("receptors") for several drugs such as cocaine (NET) or fluoxetine (5-HT transporter) 
(Bönisch and Brüss, 2006, Capela et al., 2008), but also MDMA (both) (Capela et al., 2009). 
Dopamine transporter and NET exhibit overlapping, yet distinct, substrate selectivity, 
translocation efficiency, and antagonist sensitivity (Buck and Amara, 1994, Giros et al., 1994, 
Pifl et al., 1996, Bönisch and Brüss, 2006). Other than the corresponding neurons, NET is also 
present in adrenal medulla, liver, and placenta, whereas dopamine transporter is present in 
the stomach, pancreas, and kidneys (Eisenhofer, 2001).  
The neuronal NA uptake system was first reported in the spleen and heart (Axelrod et al., 
1959, Axelrod et al., 1961). The availability of radiolabelled catecholamines enabled Axelrod 
and co-workers to examine the fate of these amines after their intravenous administration to 
laboratory animals (Axelrod et al., 1959, Axelrod et al., 1961). They observed a selective 
accumulation of radiolabelled ADR and NA in sympathetically innervated organs, which 
was dependent on intact sympathetic nerve terminals and it was inhibited by cocaine 
(Axelrod et al., 1959, Axelrod et al., 1961). It was shown that this accumulation occurred 
through the activity of NET. 
The activity of neurotransmitter transporters, like NET and dopamine transporter, is 
dependent on intracellular sodium ion (Na+) and chloride ion (Cl−) concentrations. The Na+-
gradient (extracellular concentration of Na+ is higher) across the plasma membrane is the 
main driving force, dictating the direction of the transport of neurotransmitters and co-
substrate ions (in these case Na+). The normal direction is inwards (Masson et al., 1999, 
Sonders et al., 2005, Bönisch and Brüss, 2006). The negative intracellular membrane potential 
also contributes for the above mentioned driving force and it is mainly created by the 
potassium ion (K+) gradient (Bönisch and Brüss, 2006). 
Transport of NA by NET is saturated and it is characterized by a half-saturation constant or 
Michaelis constant (Km) of about 0.8 μM; ADR is transported by NET with a Km of 2.8 μM in a 
maximum velocity two times lower than the transport of NA (Apparsundaram et al., 1997, 
Bönisch and Brüss, 2006). NET has a high affinity for NA and a somewhat lower affinity for 
ADR, while isoproterenol is not a substrate for this system (Eisenhofer, 2001, Bönisch and 
Brüss, 2006). The common structural requirement for uptake by NET is the presence of an 
ionisable nitrogen not incorporated in the aromatic ring system (Eisenhofer, 2001). 
In amphibians, an ADR specific transporter has been identified, with characteristics distinct 
from those of dopamine transporter or NET (Apparsundaram et al., 1997). In mammals, the 
presence of an ADR specific transporter was not yet clarified, however in situ hybridization 
studies indicate the absence of both dopamine transporter and NET messenger ribonucleic 
acid (mRNA) in ADR-synthesizing neurons in the brainstem of adult rats (Lorang et al., 
1994). Thus, as ADR is also cleared at these sites, these terminals might have a distinct 
catecholamine transporter from dopamine transporter or NET; as an alternative, ADR may 
act as an endocrine regulator that does not require rapid reuptake in those neurons (Lorang 
et al., 1994, Apparsundaram et al., 1997). 
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The importance of neuronal catecholamine transporters in maintaining vesicular levels of 
catecholamines is well illustrated in mutant mice lacking NET. NET is a high-affinity 
system, relatively selective for NA, with a low maximum rate of uptake, and it is important 
in maintaining releasable stores of NA (Bönisch and Brüss, 2006). The knockout NET mice 
showed depletion of NA intraneuronal stores, lack of inhibition of neuronal amine 
synthesis, protracted clearance, and elevated NA extracellular levels (Wang et al., 1999). 
Interestingly, in cyclic voltammetry experiments with the knockout NET mice, the rate of 
NA clearance was decreased by only six fold when compared to the rate of wild-type 
animals (Xu et al., 2000). The knockout NET mice behave like wild-type animals treated 
with antidepressant drugs and are hyperresponsive to locomotor stimulation with 
psychostimulants (Xu et al., 2000). 
In summary, the neuronal reuptake process aims to assure constant and high levels of 
neurotransmitters in the releasing neuron and low concentrations in the cleft (Eisenhofer, 
2001, Bönisch and Brüss, 2006). It works as an integrated part of the neurotransmitter 
recycling process, since in addition to their de novo synthesis, the stores of monoamines in 
the terminal portions of the neural fibres are also replenished by their active transport back 
to the terminals. Moreover, the reuptake system contributes to the degradation of 
catecholamines since the metabolizing enzymes are found intracellularly (Westfall and 
Westfall, 2006). Furthermore, the reuptake of catecholamines maintains the concentration 
gradient within the neuronal vesicles. Two distinct neuron carrier-mediated transport 
systems are involved: one across the axoplasmic membrane from the extracellular fluid to 
the cytoplasm, NET or dopamine transporter, and the other from the cytoplasm into the 
storage vesicles, the VMAT-2 (Bloom, 2006). The removal of catecholamines from the 
cytoplasm into the storage system by VMAT-2 acts as an amplification step for the overall 
uptake process developed by NET or dopamine transporter (Schuldiner, 1994, Sonders et al., 
2005). In a broader sense, catecholamine transporters function as part of an integrated 
system where catecholamine synthesis, release, uptake, and metabolism are regulated in a 
coordinated fashion (Eisenhofer, 2001). Therefore, neuronal catecholamine transporters 
function not only as part of metabolizing systems, but perhaps more importantly, as part of 
the recycling system, operating in series with VMAT-2 to maintain catecholamine neuronal 
stores (Eisenhofer, 2001) (Figure 3). 
8. Catecholamine extraneuronal transporters 
Catecholamines are also taken up by extraneuronal transporters. A low affinity, high 
capacity uptake for NA and ADR in the isolated perfused rat heart was found by Iversen 
(Iversen, 1963, 1965b,a). Iversen observed that radiolabelled [3H]-NA in the isolated heart 
entered into at least two intracellular pools with distinct rate constants. In fact, [3H]-NA 
entered one pool approximately seven-times faster when compared to the other pool 
(Iversen, 1963). In 1967, Malmfors demonstrated, by fluorescence microscopy, that the 
myocytes were responsible for an uptake process (Malmfors, 1967). After these discoveries, 
the neuronal NA uptake system was designated as “uptake-1” and the extraneuronal 
transport system as “uptake-2” (Iversen, 1965b). The extraneuronal uptake of 
catecholamines is mediated by organic cation transporters (OCTs), that include the classic 
corticosterone-sensitive extraneuronal monoamine transporter and traditionally named 
“uptake-2” that nowadays is called OCT3 (Eisenhofer, 2001, Schömig et al., 2006). Other 
members of this family are: OCT1 and OCT2.  
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All three OCTs can transport catecholamines in addition to a wide variety of other organic 
acids, including 5-HT, histamine, choline, spermine, guanidine, and creatinine 
(Eisenhofer, 2001). The affinity of extraneuronal monoamine transporter for NA is rather 
low (Km > 0.5 mM), which is compensated by its high capacity (high turnover number). 
The transport efficiency of OCT1 and OCT2 for dopamine, NA, ADR, and 5-HT is usually 
low (Schömig et al., 2006).  
OCTs share common features. A single positive charge is required to be an OCT substrate, 
while uncharged, doubly charged or negatively charged substances are not transported by 
OCTs (Schömig et al., 2006). A decrease in extracellular pH and the depolarization of the 
cytoplasmatic membrane will reduce the OCT activity. The OCT mediated transport is 
independent of Na+ and Cl− gradients and all three OCTs are transporters, not just channels, 
as shown by trans-stimulation experiments. OCT1, OCT2 or extraneuronal monoamine 
transporter may mediate electrogenic uniport of a substrate or electroneutral exchange of 
two substrates (antiport). The OCTs are relatively resistant to the inhibitors of the neuronal 
transporters such as desipramine (Eisenhofer et al., 1991, Schömig et al., 2006), but are 
inhibited by steroids, such as corticosterone, and the O-methylated metabolites of 
catecholamines, like normetanephrine and metanephrine (Eisenhofer, 2001, Costa et al., 
2009a, Nissinen and Männistö, 2010). Other compounds, like GF120918, were shown to 
inhibit extraneuronal monoamine transporter at low concentrations in isolated rat 
cardiomyocytes (Costa et al., 2009a). 
Extraneuronal monoamine transporter (OCT3) is expressed in many but not all tissues. The 
expression varies greatly between organs and during organ development (e.g. in placenta). 
Consistently, high expression has been reported for placenta and heart (Eisenhofer, 2001). 
Other reports indicate high extraneuronal monoamine transporter expression in the area 
postrema (Haag et al., 2004, Vialou et al., 2004) and very low in the kidneys (Eisenhofer, 
2001). Interestingly, extraneuronal monoamine transporter expression has been also 
suggested to occur in neurons (Kristufek et al., 2002, Shang et al., 2003). 
For NA, the uptake by NET is more relevant for signal termination than extraneuronal 
uptake. It has been estimated that the sympathetic nerves remove approximately 87% of 
released NA by NET, while 5% is removed by extraneuronal monoamine transporter. The 
remainder 8% is diffused into the circulation (Eisenhofer, 2001). This data, however, does 
not necessarily reflect the relative importance of the two processes. The proximity of the 
neuronal transporters to the location of catecholamine release (when compared to 
extraneuronal transporters) implies that the transmitter removed by extraneuronal transport 
has a higher duration and wider range of action. Extraneuronal uptake, therefore, may be 
particularly important for the removal of neuronal released catecholamines in tissues where 
high concentrations of adrenergic receptors exist (Eisenhofer, 2001). The clearance of 
circulating catecholamines is primarily mediated by non neuronal mechanisms, with liver 
and kidney accounting for over 60% (Eisenhofer, 2001, Westfall and Westfall, 2006). As 
stated above, most NA released by sympathetic nerves is removed by neuronal reuptake, 
which is in contrast with that of ADR. ADR when secreted directly into the bloodstream 
from the adrenal medulla is predominantly inactivated by extraneuronal uptake and 
metabolism. ADR has lower affinity for neuronal uptake than NA and consequently the 
neuronal process contributes approximately 50% less for its elimination when compared 
with NA (Iversen, 1965a). In contrast, ADR is removed by extraneuronal uptake 2-3 times 
more efficiently than NA (Iversen, 1965b, Eisenhofer et al., 1992b).  
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In short, when compared to NET, extraneuronal monoamine transporter exhibits lower 
affinity (i.e. higher Km) for catecholamines, favours ADR and isoproterenol over NA or 
dopamine, and shows a higher maximum rate for catecholamine uptake (i.e. higher 
maximum velocity) (Iversen, 1965a, b, Eisenhofer et al., 1992b, Eisenhofer, 2001, Schömig et 
al., 2006). Extraneuronal monoamine transporter is not Na+-dependent and displays a 
completely different profile of pharmacological inhibition (Schömig et al., 2006, Westfall and 
Westfall, 2006). Thus, in contrast to the importance of NET in the clearance of neuronal 
released catecholamines, clearance of circulating catecholamines is predominantly made by 
non-neuronal mechanisms (Eisenhofer, 2001). 
9. Metabolism and action termination 
The pharmacological actions of NA and ADR are terminated by: (i) reuptake into nerve 
terminals by NET; (ii) uptake at extraneuronal sites by extraneuronal monoamine 
transporter, OCT1, or OCT2; and (iii) metabolic transformation. Catecholamines undergo a 
complex metabolic fate, mediated by several enzymes, including aldehyde reductase, aldose 
reductase, aldehyde dehydrogenase, alcohol dehydrogenase, catechol-O-methyltransferase 
(COMT), dopamine ǃ-hydroxylase, monoamine oxidase (MAO) type A and B, monoamine-
preferring phenolsulfotransferase, and PNMT (Dooley, 1998, Goldstein et al., 2003). In vivo, 
two of the most important enzymes responsible for the metabolic transformation of 
catecholamines are MAO and COMT (Westfall and Westfall, 2006). 
9.1 Monoaminoxidase metabolism 
MAO was first described as tyramine oxidase by Mary Hare-Bernheim in 1928, since it 
catalyses the oxidative deamination of tyramine. This enzyme was found to oxidize several 
monoamines, including catecholamines, i.e. dopamine, NA, and ADR, and also 5-HT. MAO 
[amine: oxygen oxidoreductase (deaminating)] catalyses the following reaction:  
RCH2NH2 + H2O + O2 → RCHO + NH3 + H2O2 
MAO acts on primary amines and also on some secondary and tertiary amines (Nagatsu, 
1991). It is located in the outer membrane of mitochondria (Schnaitman et al., 1967) both in 
neuronal and extraneuronal cells (Trendelenburg, 1988) (Figure 3). It is a flavo-protein, with 
flavin adenine dinucleotide as cofactor (Kearney et al., 1971). Two forms of MAO exist, i.e. 
MAO-A and MAO-B (Johnston, 1968). In humans, MAO-A is abundant in the brain, liver, 
and in the syncytiotrophoblast layer of term placenta, whereas liver, lungs, platelets, 
lymphocytes, osteocytes that surround the blood vessels, and the intestine are rich in MAO-
B (Abell and Kwan, 2001, Nagatsu, 2004). In the human brain, MAO-A is located in the 
catecholamine-containing regions, with the highest levels being found in locus ceruleus. 
MAO-B is prominent in the dorsal raphe nuclei, which are known to have serotonergic 
neurons. MAO-B is also present in the posterior hypothalamus and in glial cells (Abell and 
Kwan, 2001, Nagatsu, 2004).  
5-HT, NA, and ADR are preferential substrates for MAO-A, and clorgyline and Ro 41-1049 
are MAO-A inhibitors (Johnston, 1968, Kitaichi et al., 2010); MAO-B prefers ǃ-
phenylethylamine as a substrate and it is inhibited by deprenyl and lazabemide (Knoll et al., 
1978, Kitaichi et al., 2010). Dopamine, tyramine, and tryptamine are oxidized with equal 
affinity by MAO-A and MAO-B (Glover et al., 1977). Pargyline inhibits both MAO-A and 
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MAO-B (Blaha et al., 1996, Carvalho et al., 2001, Carmo et al., 2003, Duarte et al., 2004). 
MAO-A appears to be the main enzyme in the metabolism of 5-HT and NA, while the 
location of MAO-B, abundant in serotonergic neurons, remains under debate (Abell and 
Kwan, 2001).  
In the brain of MAO-A-deficient mouse pups, NA levels increased up to two-fold, while a 
small increase in dopamine levels was observed. Borderline mental retardation and 
abnormal behavioural are observed in humans with selective MAO-A deficiency. Severe 
mental retardation in patients with combined MAO-A/MAO-B deficiency and Norrie 
disease are also observed (Lenders et al., 1996). Human males from a Dutch family with a 
complete deletion of the mao-a gene in the X chromosome were reported to show abnormal 
aggressive behaviour (Brunner et al., 1993), as observed in adult mice (Cases et al., 1995). 
MAO-A-deficient adult male mice show enhanced aggressive behaviour and enhanced 
emotional learning, probably due to elevated levels of 5-HT in the brain in the pup stage 
(Cases et al., 1995, Kim et al., 1997). Furthermore, MAO-A knockout mice exhibited a 
dramatic reduction of defensive and fear-related behaviours in the presence of predator-
related cues, such as predator urine or an anaesthetized rat (Godar et al., 2010). 
All regions of the brain of MAO-B-deficient mouse pups showed increased levels of ǃ-
phenylethylamine (Lenders et al., 1996), especially in striatum and prefrontal cortex 
(Bortolato et al., 2009). The MAO-B knockout mice show behavioural disinhibition and 
decrease anxiety-like responses partially through a regional increase in ǃ-phenylethylamine 
levels (Bortolato et al., 2009). In contrast to the borderline mental retardation and abnormal 
behavioural phenotype in subjects with selective MAO-A deficiency and the severe mental 
retardation in patients with combined MAO-A/MAO-B deficiency and Norrie disease, the 
MAO-B-deficient human subjects neither exhibited abnormal behaviour nor mental 
retardation except increased reactivity to stress (Grimsby et al., 1997). The subjects with the 
mao-b gene deletion have complete absence of platelet MAO-B activity and have increased 
brain levels and urinary excretion of ǃ-phenylethylamine (Lenders et al., 1996). In fact, the 
inhibition of MAO-B indicates that this form of MAO has a lower contribution to the 
metabolism of endogenous catecholamines and of their O-methylated metabolites 
(Eisenhofer and Finberg, 1994). 
9.2 Catechol-O-methyl transferase metabolism  
Another important catecholamine-metabolizing enzyme (COMT) was first described and 
purified by Axelrod (Axelrod, 1958, Axelrod and Tomchick, 1958) (Figure 3). One single 
gene for COMT codes for both soluble COMT and membrane-bound COMT. That gene has 
different transcription starting sites. COMT is an intracellular enzyme, the most abundant 
form being the soluble COMT with a minor fraction as membrane bound COMT (Mannisto 
and Kaakkola, 1999). COMT catalyses the transfer of the methyl group of S-adenosyl-L-
methionine to one of the hydroxyl groups in the catechol in the presence of magnesium ion 
(Mg2+) (Mannisto and Kaakkola, 1999). COMT is widely distributed throughout the body. 
High levels of COMT are found in the liver, proximal tubular epithelial cells of the kidneys, 
and other extraneuronal cells, namely adrenomedullary chromaffin cells (Eisenhofer et al., 
1998, Mannisto and Kaakkola, 1999). However, little or no COMT is found in sympathetic 
neurons. In the presynaptic terminals of the brain, no significant COMT is detected, but it is 
reported in some postsynaptic neurons and glial cells. The physiological substrates of 
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COMT include L-3,4-dihydroxyphenylalanine, all three endogenous catecholamines 
(dopamine, NA, and ADR), their hydroxylated metabolites, catecholestrogens, ascorbic acid, 
and dihydroxyindolic intermediates of melanin (Mannisto and Kaakkola, 1999, Nissinen 
and Männistö, 2010).  
In COMT knockout mice, minor behaviour changes were detected and the neurochemistry 
of catecholamines in the brain is virtually unaltered (Gogos et al., 1998). Mutant mice 
showed sexually dimorphic and region-specific changes of dopamine levels, notably in 
the frontal cortex. Mutant male mice have almost a three-fold increase of dopamine levels 
in the frontal cortex, while no changes were observed in the striatum or hypothalamus. In 
mutant female mice no alterations in dopamine levels were observed when compared to 
the wild type (Gogos et al., 1998). Despite the complete lack of comt gene in homozygous 
mice, residual HVA levels were detectable in several brain areas, revealing a possible and 
still unidentified methylation pathway in the brain (Gogos et al., 1998). Female knockout 
mice showed impaired emotional reactivity, while heterozygous males were more 
aggressive (Gogos et al., 1998). The work by Gogos and colleagues suggested that the 
importance of COMT in the emotional and social behaviour has probably been 
undervalued and the complete lack of COMT can be partially compensated, at least in 
mice (Gogos et al., 1998). 
9.2.1 The cross-talk between catecholamine catabolic enzymes and transporters 
Of relevance, the main mechanism that reduces the life span of catecholamines in the 
extracellular space is their uptake by active transport and not their enzymatic metabolism. It 
has been shown that NET inhibitors (e.g., cocaine, imipramine, and desipramine) potentiate 
the effects of the neurotransmitters, while inhibitors of MAO and COMT have relatively 
little immediate effect (Gonçalves et al., 1989, Eisenhofer, 1994, Eisenhofer and Finberg, 
1994, Friedgen et al., 1994, Blaha et al., 1996, Friedgen et al., 1996). Early studies in isolated 
tissues showed that the inhibition of MAO or COMT could limit the ability of neuronal and 
extraneuronal uptake to clear extracellular catecholamines (Furchgott and Garcia, 1968, 
Belfrage et al., 1977). More recent in vivo studies however indicate that inhibition of one 
enzyme under normal physiological conditions has little effect on the overall catecholamine 
clearance and on their extracellular or circulating levels (Eisenhofer, 1994, Eisenhofer and 
Finberg, 1994, Friedgen et al., 1994, Blaha et al., 1996, Friedgen et al., 1996). Only when MAO 
and COMT are both inhibited or subjected to saturating concentrations of substrate, the 
clearance of catecholamines is significantly impaired (Eisenhofer, 1994, Friedgen et al., 1996). 
To confirm the redundancy of metabolizing systems, in MAO-A-deficient humans or rats a 
marked decrease in deaminated catecholamine metabolites and a concomitant marked 
elevation of O-methylated amine metabolites occur (Eisenhofer and Finberg, 1994, Lenders 
et al., 1996). These neurochemical changes are only slightly exaggerated in patients with 
combined lack of MAO-A and MAO-B (Lenders et al., 1996). 
The activity of metabolizing enzymes can influence the catecholamine net transport and the 
extracellular levels of catecholamines. Moreover, the metabolizing enzymes are always 
required for the irreversible chemical alteration of catecholamines following neuronal or 
extraneuronal uptake. Nevertheless, Trendelenburg stated that understanding the 
www.intechopen.com
 
Neuroscience – Dealing with Frontiers 16
interactions and the functions of the active transport and metabolizing processes is very 
relevant as they function as “pump and leak systems with enzyme(s) inside” 
(Trendelenburg, 1988, 1990).  
An integrated vision explains the results found in vivo. In fact, the presence of only one 
catecholamine-metabolizing enzyme, MAO, in neuronal systems would lead to the 
assumption that inhibition of this enzyme would impair the catecholamine’s neuronal 
uptake by changing the concentration gradient. However, the additional presence of VMAT-
2 maintains the axoplasmic catecholamine levels low. Furthermore, VMAT-2 has higher 
affinity for NA than MAO, which implies that over 70% of the recaptured NA through NET 
is sequestered into storage vesicles before being metabolized (Bloom, 2006). Therefore, 
under normal physiological conditions, the inhibition of MAO has little effect (Graefe and 
Trendelenburg, 1970, Graefe and Henseling, 1983). Rather than impairing the catecholamine 
uptake, short-term inhibition of intraneuronal MAO leads to higher retention of recaptured 
transmitter by VMAT-2 and, thus, an apparent increase in the net uptake of the transmitter 
(Furchgott and Garcia, 1968). In the long term, if vesicular storage capacity is overwhelmed, 
inhibition or saturation of intraneuronal MAO can lead to a decrease in neurotransmitter’s 
uptake (Trendelenburg et al., 1972).  
9.3 The metabolites of catecholamines  
Complex and dynamic processes are involved in the metabolism of catecholamines, either 
intracellularly or even after their release into the extracellular fluid. In both neuronal and 
extraneuronal metabolizing systems, the inactivation of catecholamines occurs in a 
coordinated fashion, with uptake being followed by metabolism (Graefe and Henseling, 
1983). Most of the metabolism of catecholamines takes place in the same cells where they are 
produced, even before their exocytotic release (Figure 4). Dihydroxyphenylglycol (DHPG, 
3,4-dihydroxyphenylethylene glycol) constitutes the main NA metabolite before NA release 
or reuptake. DHPG is also a deaminated metabolite of ADR (Eisenhofer and Finberg, 1994, 
Goldstein et al., 2003). DHPG is formed from NA in the cytoplasm of sympathetic nerves by 
sequential deamination of NA by MAO to form dihydroxyphenylglycoaldehyde. This 
aldehyde is reduced by aldehyde reductase or aldose reductase to form DHPG or it is 
oxidized by aldehyde dehydrogenase to form 3,4-dihydroxymandelic acid. DHPG diffuses 
rapidly across the membrane of the cell into the extracellular fluid and into extraneuronal 
cells. In the extraneuronal cells, DHPG is metabolized by COMT to form 3-methoxy-4-
hydroxy-phenylethylene glycol, or it overflows into the bloodstream (Eisenhofer and 
Finberg, 1994, Goldstein et al., 2003). Also, the decrease in plasma concentrations of 
endogenous DHPG and 3,4-dihydroxyphenylacetic acid after inhibition of MAO-A, but not 
MAO-B, corroborates that NA is a better substrate for the A isoform (Eisenhofer and 
Finberg, 1994). 
COMT has a substantial importance in the metabolism of the deaminated metabolites of NA 
and dopamine, as corroborated by the increase of plasma levels of 3,4-dihydroxyphenylacetic 
acid and DHPG after COMT inhibition (Eisenhofer and Finberg, 1994). Alternatively, COMT 
can catalyse the O-methylation of NA to normetanephrine, of ADR to metanephrine, of L-3,4-
dihydroxyphenylalanine to 3-methoxytyrosine, and of dopamine mainly to 3-
methoxytyramine (Eisenhofer and Finberg, 1994, Goldstein et al., 2003).  
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Fig. 4. Representative pathway of the most common metabolic pathways of adrenaline 
(ADR) and noradrenaline (NA). ADR is synthesized from NA through phenylethanolamine 
N-methyltransferase (PNMT) catalysis. NA is metabolized preferably by monoamine 
oxidase (MAO) to dihydroxyphenylglycoaldehyde (DOPEGAL) that is reduced by aldehyde 
reductase (AR) to form dihydroxyphenylglycol (DHPG). ADR is preferably metabolized by 
catechol-O-methyltransferase (COMT) resulting in metanephrine (MN). MN can be further 
metabolized by MAO to 3-methoxy-4-hydroxyphenyl-glycoaldehyde (MOPGAL) and by 
aldehyde reductase (AR) to form 3-methoxy-4-hydroxy-phenylethylene glycol (MHPG). 
MHPG is further metabolized and can be transformed to vanillylmandelic acid (VMA) by 
alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH). VMA is the main 
catecholamine metabolite in urine (adapted from reference Goldstein et al., 2003).  
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In adrenal chromaffin cells, as they contain both MAO and COMT, the deamination and O-
methylation coexist. The COMT present in chromaffin cells is mainly membrane bound 
COMT while soluble COMT is found in the majority of other tissues (namely liver and 
kidneys). Membrane bound COMT has a higher affinity for catecholamines than the soluble 
COMT (Roth, 1992). As a result, in adrenal chromaffin cells, leakage of NA and ADR from 
storage granules leads to substantial intracellular production of the O-methylated 
metabolites, normetanephrine and metanephrine. In humans, about 93% of circulating 
metanephrine and between 25% to 40% of circulating normetanephrine result from the 
catecholamines metabolized within adrenal chromaffin cells (Eisenhofer et al., 2004). 
In most cells, the O-methylated compounds that contain amine groups undergo further 
metabolic alterations by MAO. Deamination of 3-methoxytyramine yields HVA and 
deamination of normetanephrine and metanephrine yields 3-methoxy-4-hydroxy-
phenylethylene glycol. 3-Methoxy-4-hydroxy-phenylethylene glycol in human plasma is a 
very important metabolite with multiple sources, including (i) deamination of 
normetanephrine after its cellular uptake; (ii) O-methylation of DHPG after its uptake from 
the circulation; and (iii) O-methylation of DHPG after its uptake from the interstitial fluid 
but before its entrance into the circulation. Of the previously mentioned sources, the most 
relevant is the last (Eisenhofer and Finberg, 1994). The fate of circulating 3-methoxy-4-
hydroxy-phenylethylene glycol is complex and includes sulfation, glucuronidation, urinary 
excretion, and specially conversion to methoxy-4-hydroxymandelic acid [generally, called 
vanillylmandelic acid (VMA)] through the hepatic sequential oxidation of circulating 3-
methoxy-4-hydroxy-phenylethylene glycol by alcohol dehydrogenase and aldehyde 
dehydrogenase (Goldstein et al., 2003). In fact, the major product of urinary excretion and 
also an important plasma metabolite of adrenergic catecholamines is VMA (Goldstein et al., 
2003) (Figure 4).  
The formation of normetanephrine occurs after NA extraneuronal uptake and metabolism. 
Due to the importance of the reuptake and intraneuronal deamination of endogenously 
released NA, plasma levels of normetanephrine are lower than those of DHPG, despite the 
similar plasma clearance of these two compounds. The rate of extra adrenal production of 
normetanephrine, although low, still provides a unique marker of NA extraneuronal 
metabolism. Accordingly, during MAO-A inhibition, normetanephrine and metanephrine 
levels increase as COMT becomes more relevant in the metabolism of NA (Eisenhofer and 
Finberg, 1994).  
As stated, adrenomedullary chromaffin cells contain both MAO and COMT and, in 
agreement with the different affinities between extraneuronal and neuronal uptake, ADR is 
less metabolized by MAO than NA, but it is a better substrate for COMT (Paiva and 
Guimarães, 1978, Eisenhofer and Finberg, 1994). Because of these differences, extraneuronal 
uptake and O-methylation clear more circulating ADR than NA (Axelrod et al., 1959, 
Eisenhofer, 2001, Goldstein et al., 2003) and metanephrine is the major metabolite of ADR 
(Axelrod et al., 1959, Goldstein et al., 2003). 
In cells that contain monoamine-preferring phenolsulfotransferase, the non-acid 
metabolites, methoxytyramine, normetanephrine, metanephrine, and 3-methoxy-4-hydroxy-
phenylethylene glycol undergo extensive sulphate-conjugation. The urinary metabolites, 
resulting from monoamine-preferring phenolsulfotransferase metabolization are usually 3-
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methoxy-4-hydroxy-phenylethylene glycol-SO4, normetanephrine-SO4, and metanephrine-
SO4 (Eisenhofer et al., 2004). 
Glucuronides of methoxytyramine, normetanephrine, metanephrine, and 3-methoxy-4-
hydroxy-phenylethylene glycol are also formed and they may be excreted in the bile. When 
these glucuronides enter into the circulation, they are eliminated in the urine (Eisenhofer et 
al., 2004). 
Of relevance, the oxidative deamination of catecholamines by MAO leads to another 
relevant product, hydrogen peroxide (H2O2) which subsequently may be converted into the 
highly reactive hydroxyl radical (HO●) (Valko et al., 2007), that may cause oxidative stress-
related damage (Carvalho et al., 2001, Duarte et al., 2004, Vaarmann et al., 2010, Costa et al., 
2011).  
9.3.1 Levels of catecholamines and their metabolites in the plasma and urine 
Catecholamines enter the plasma mainly after their leakage from the synaptic cleft to the 
circulation or after the secretion of catecholamines by the adrenal medulla (Esler et al., 1990, 
Goldstein et al., 2003). The bulk of NA in the plasma results mainly from sympathetic 
overflow, while the majority of plasma ADR is formed by adrenal medulla secretion (Esler 
et al., 1990, Goldstein et al., 2003). The metabolites of NA and ADR also spill into the plasma 
after intraneuronal metabolism (namely oxidative deamination by MAO) or extraneuronal 
metabolism (preferentially COMT-methylation), since the majority of the metabolism occurs 
even before the catecholamines reach the circulation (Goldstein et al., 2003). The most 
abundant human plasma metabolites are VMA, 3-methoxy-4-hydroxy-phenylethylene 
glycol and its sulphate metabolite (Goldstein et al., 2003). The main human plasma catechols 
are the three catecholamines, their precursor, L-3,4-dihydroxyphenylalanine, and their 
deaminated metabolites, 3,4-dihydroxyphenylacetic acid from dopamine, and DHPG from 
NA (Goldstein et al., 2003) (Figure 4).  
In humans, the sympathetic nerves of kidneys and skeletal muscles are the major sources of 
plasma NA, each contributing with approximately 25% of the total (Esler et al., 1984a, Esler 
et al., 1984b). The sympathetic innervations of the human heart, skin, gastrointestinal tract, 
lungs, and liver are responsible for a minor percentage of total plasma NA, but equally 
important (Esler et al., 1984a, Esler et al., 1984b, Goldstein et al., 1988, Esler and Kaye, 2000).  
The rate of NA entrance into the arterial plasma (“total body spillover”) can be measured 
and in healthy people averages 0.3 to 0.5 μg/min (Goldstein et al., 2003). Key players in the 
rate of NA spillover include the rate of NA release, and consequently nerve firing velocity 
and density, but also regional blood flow, capillary permeability, neuronal NA uptake, and 
NA metabolism (Esler et al., 1990). These key aspects have to be taken into account when 
interpreting NA overflow as an index of sympathetic activity. In fact, when comparing the 
levels of NA release into interstitial fluid to circulation with NA spillover, the NA release 
into interstitial fluid in kidneys averages 3 times, in skeletal muscle 12 times, and in the 
heart over 20 times the NA spillover, due to the efficient local neuronal reuptake of NA. 
(Goldstein et al., 2003).  
The majority of plasma ADR in physiological conditions results from the stimulation of 
adrenal medulla (Goldstein et al., 2003); it is assumed that ADR overflow from adrenergic 
nerves is not very relevant (Esler et al., 1990). The only exception is the heart, which at very 
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high stimulation rates can contribute significantly for ADR spillover into the plasma 
(Peronnet et al., 1988, Johansson et al., 1997).  
Plasma levels of ADR in healthy volunteers at rest are as low as 30 pM, while NA reaches 1 
nM (Wheatley et al., 1985, Goldstein et al., 2003). Spillover of ADR to arterial plasma in 
healthy resting humans is typically 30-100 pg/mL, while it can reach 200-600 ng/mL for NA 
(Esler et al., 1990). Any alteration in the metabolism of catecholamines or disruption of their 
transport mechanisms might lead to abnormal high concentrations of these substances 
(Lameris et al., 2000). Elevated levels of circulating and interstitial catecholamines are found 
in arrhythmias, myocardial necrosis (Lameris et al., 2000, Behonick et al., 2001), heart failure, 
(Esler and Kaye, 2000), myocardial ischemia (Lameris et al., 2000, Akiyama and Yamazaki, 
2001, Killingsworth et al., 2004, Kuroko et al., 2007), exercise (Kjaer, 1998), 
pheochromocytoma (Gerlo and Sevens, 1994), hypoglycaemia, haemorrhagic hypotension, 
circulatory collapse, distress (Goldstein et al., 2003), and cirrhosis (Esler et al., 1990). The 
administration of amphetamines can also lead to peaks of plasmatic levels of biogenic 
catecholamines. In fact, after high doses of d-amphetamine in rats, levels of plasmatic ADR 
and NA reached 146 nM and 418 nM, respectively (Carvalho et al., 1997).  
The levels of urinary and plasma catecholamine or metabolites can also indicate a higher 
sympathetic overflow or metabolism impairment (Esler et al., 1990, Brunner et al., 1993, 
Lenders et al., 1996, Behonick et al., 2001, Goldstein, 2003). In fact, the measurement of 
DHPG gives important information of NA sympathetic nerve neuronal uptake and turnover 
(Esler et al., 1990, Goldstein et al., 2003). The DHPG values reflect the sum of vesicular 
leakage, NA deamination (which is mainly neuronal) and reuptake (Eisenhofer et al., 1992a, 
Goldstein et al., 2003). DHPG plasma levels can reach 4.7 nM in healthy volunteers 
(Goldstein et al., 2003).  
Formation of normetanephrine in the body occurs after extraneuronal uptake and 
metabolism of NA in the sympathetic terminals, as well as from the O-methylation of NA 
within the adrenal medulla by COMT. Because of the high importance of reuptake and 
intraneuronal deamination of NA, plasma levels of normetanephrine (~0.3 nM) are 
significantly lower than those of DHPG (Goldstein et al., 2003).  
O-Methylation is the main metabolic pathway of ADR in man (Labrosse et al., 1958). 
Metanephrine constitutes a major metabolite of ADR before its release into the 
extracellular fluid (Labrosse et al., 1958, Axelrod et al., 1959). Plasma metanephrine levels 
are roughly the same as plasma normetanephrine levels, although the levels of plasma 
NA are about 5- to 10-fold higher than the levels found for ADR. The levels of 
metanephrine result from the high rate of production of ADR in adrenomedullary 
chromaffin cells, the metabolism of adrenomedullary catecholamines by COMT 
(Goldstein et al., 2003), and the relatively high affinity of COMT for circulating ADR 
(Paiva and Guimarães, 1978, Eisenhofer and Finberg, 1994). 
As already stated, 3-methoxy-4-hydroxy-phenylethylene glycol in human plasma has 
multiple sources, the main being O-methylation of DHPG after its uptake from the 
interstitial fluid but before its entrance into the circulation. The metabolic fate of the 
circulating 3-methoxy-4-hydroxy-phenylethylene glycol is complex and includes sulfation, 
glucuronidation, and specially conversion to VMA (Goldstein et al., 2003). 3-Methoxy-4-
hydroxy-phenylethylene glycol and VMA constitute the major non sulphate catecholamine 
metabolites, reaching plasmatic values of 30 and 20 nM, respectively (Goldstein et al., 2003). 
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L-3,4-dihydroxyphenylalanine is the precursor of catecholamines and the product of the 
rate-limiting step of catecholamine synthesis. L-3,4-dihydroxyphenylalanine therefore 
occupies a crucial role in the catecholaminergic system. In humans, plasma levels of L-3,4-
dihydroxyphenylalanine exceed those of NA about 10-fold, reaching 8.9 nM (Goldstein et 
al., 2003). 
Some catecholamine storage vesicle elements are released during exocytosis like 
chromogranin A, DhB, and neuropeptide Y. Their plasma values can be used as an index of 
the neuroendrocrine system activation (Esler et al., 1990).  
All catecholamines are ultimately excreted in urine, either in their native form or as 
metabolites (Esler et al., 1990, Goldstein et al., 2003). Nevertheless, in urine, only a small 
fraction of catecholamines is present in their unaltered form (Esler et al., 1990) and NA 
urinary excretion represents only 1-2% of the total NA synthesized. VMA is the major 
catecholamine metabolite excreted in the urine and 33 μM of VMA can be eliminated each 
24 h (Gerlo and Sevens, 1994). The sulphate derivatives of 3-methoxy-4-hydroxy-
phenylethylene glycol, normetanephrine, and metanephrine are the bulk of the other 
urinary metabolites (Eisenhofer et al., 2004). The use of urinary excretion levels of 
catecholamines and/or of their metabolites to estimate total body catecholamine turnover 
and plasma levels has to be very cautious. Urinary excretion depends on renal blood flow 
and renal function, thus it has some inter-individual variations (Fluck, 1972). 
9.4 Another pathway to degrade catecholamines 
The metabolization of catecholamines is generally attained either by deamination via MAO 
or O-methylation by COMT. However, the chemical alteration of catecholamines by other 
enzymes or through oxidative processes is also a probable pathway to the chemical 
alteration of the transmitters (Richter, 1940)(Figure 5). When the enzymes dealing with the 
catabolism of catecholamines are unable to cope efficiently, their levels rise and 
catecholamines can undergo oxidation. The oxidation rate is faster under enzymatic or metal 
catalysis (Heacock, 1959, Bindoli et al., 1992, Foppoli et al., 1997), in the presence of the 
superoxide anion (O2–) or high pH (West, 1947, Spencer et al., 1995, Costa et al., 2007). 
Although at physiological pH, the oxidation of catecholamines seems to occur very slowly, 
it has been found to occur in vivo namely in the septic shock (Macarthur et al., 2000). The 
oxidation of catecholamines ultimately produces a family of indole semiquinonic/quinonic 
species usually termed catecholaminochromes because of their orange-reddish colour 
(Heacock and Mahon, 1958). The oxidation of aqueous extracts of mammal suprarenal 
capsules was first reported by Vulpian (Vulpian, 1856). The oxidation products of ADR were 
crucial for the indirect quantification of ADR for many years, since adrenolutin and 
adrenochrome are easily detected by UV/VIS or by fluorometric methods (Annrsten et al., 
1949, Fischer and Bacq, 1950, Ludemann et al., 1955, Remião et al., 2003, Ochs et al., 2004). 
Generally speaking, catecholamines may be oxidized to an unstable o-semiquinone that, 
after deprotonation and loss of a second electron, gives rise to the corresponding o-quinone. 
For ADR, at physiological pH, partial deprotonation of the amine group of the side chain 
leads to an irreversible 1,4-intramolecular cyclization, a reaction that occurs through 
nucleophilic attack of the nitrogen atom at position 6 of the quinone ring, to form 
“leucoadrenochrome”; leucoadrenochrome is subsequently oxidized to form adrenochrome 
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(Heacock and Mahon, 1958, Bindoli et al., 1992, Bindoli et al., 1999). This indole is often 
represented as a zwitterionic structure in aqueous solutions (Heacock and Mahon, 1958, 
Remião et al., 2003, Costa et al., 2007) (Figure 5). In summary, the oxidation of 
catecholamines occurs through two-stages whereby a total of four electrons is removed and 
an indole is formed by cyclization (Costa et al., 2011). 
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Fig. 5. Postulated pathway for the oxidation of catecholamines. The oxidation process of 
catecholamines initially involves their conversion to o-quinones through o-semiquinones 
intermediates. The o-semiquinone reduces oxygen resulting in superoxide anion (O2●–). The 
o-quinone can undergo an irreversible 1, 4-intramolecular cyclization, forming 
leucoaminonochrome. The formation of aminochrome from leucoaminochrome is a reaction 
where a total of two electrons are removed and leucoaminochrome semiquinone is the 
intermediary with O2●– as a by-product. Aminochrome formed can lead to the formation of 
aminolutins. 
Adrenochrome is the most studied aminochrome due to its stability (Heacock, 1959, Rupp et 
al., 1994). When adrenochrome is formed and ADR still exists in solution, adrenochrome 
accelerates the oxidation process of the remaining ADR (Bindoli et al., 1999, Costa et al., 2007). 
Furthermore, the yield of adrenochrome increases if ADR semi-quinone reacts with O2 to form 
O2– (Costa et al., 2007). This seems to be a general phenomenon of aminochromes, since it 
occurs also with the other catecholamines (Heacock, 1959, Bindoli et al., 1992).  
Once formed, the aminochromes can be transformed into melanins, since they are reactive 
compounds that easily undergo a series of reactions among them. In vivo, this oxidation 
pathway may be more complex, since other factors such as metal ions or other nucleophilic 
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groups can be involved (Spencer et al., 1998, Bindoli et al., 1999, Spencer et al., 2002, Costa et 
al., 2007, Costa et al., 2009a). 
At physiological pH, the oxidation pathway of biogenic catecholamines is similar, as they 
share similar intermediates, however their stability is fairly different (Rupp et al., 1994). The 
rate of internal cyclization determines the probability of nucleophilic attack to the quinone 
intermediates (Rupp et al., 1994, Spencer et al., 1995, Alhasan and Njus, 2008). Thus, if the 
internal cyclization rate is low, the quinone is likely to be attacked by external nucleophilic 
groups such as sulfhydryl (-SH), hydroxyl (-OH), and amine (-NH2) groups. The slowest 
cyclization rate is observed for dopamine, while ADR has the higher cyclization rate, 140 
times higher than NA. Thus, the probability of external nucleophilic attack to occur is as 
following: dopamine > NA > ADR (Rupp et al., 1994). In fact, dopamine oxidized forms 
were found bound to proteins, as well as to other nucleophilic molecules, as cysteine or 
glutathione (Fornstedt et al., 1990, Patel et al., 1991, Segura-Aguilar et al., 1997, Byington, 
1998, Spencer et al., 1998, Spencer et al., 2002, Miyazaki et al., 2006). Pathognomonic 
significance has been given to these products, namely in Parkinson’s disease (Spencer et al., 
1995, Shen et al., 1996, Spencer et al., 1998). As stated, the fastest cyclization rate occurs in 
ADR (Bindoli et al., 1992); however, GSH adducts and quinoproteins of ADR have been 
found in cells, thus showing that ADR quinone can also undergo attack from cellular 
nucleophiles (Costa et al., 2007, Costa et al., 2009a, Costa et al., 2009c). These changes can 
ultimately cause cellular injury (Costa et al., 2011).  
10. Adrenergic receptors 
10.1 Historic introduction and background 
More than one hundred years ago, Langley proposed, for the first time, the idea of 
transmitter receptors, by stating “(…) neither the poisons nor the nervous impulse act 
directly on the contractile substance of the muscle but on some accessory substance. Since 
this accessory substance is the recipient of stimuli which it transfers to the contractile 
material, we may speak of it as the receptive substance (…)” (Langley, 1905).  
The receptors for NA and ADR are nowadays called adrenoceptors. The adrenoceptors are 
the cell membrane sites where NA and ADR act. Several discoveries were performed before 
the concept of adrenoceptors was fully accepted. Dale in 1905 verified that the pressor effect 
of ADR was reversed by ergotoxine into a depressor effect. Later on, Barger and Dale 
verified that ADR when injected was able to dilate some vascular beds while constricting 
others (Barger and Dale, 1910). These facts were ignored until 1948 when Ahlquist 
performed a series of experiments with several sympathomimetic amines. He concluded 
that the variation in the pharmacological responses of several sympathomimetic agonists in 
different organs was related to the different types of receptors involved (Ahlquist, 1948). To 
the first type of adrenoceptors, he called ǂ and to the second ǃ (Ahlquist, 1948). The 
scientific contemporary community was not prompt to accept this idea and the theory of 
two different “sympathins” remained (Cannon and Rosenblueth, 1933). More than ten years 
later other works confirmed the theory by Ahlquist through the identification of selective 
antagonists for the two receptor families: phentolamine and ergotamine for ǂ-
adrenoceptors; dichloroisoprenaline (Powell et al., 1958) and propranolol for ǃ-
adrenoceptors (Black et al., 1964).  
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The development of more selective drugs and the use of molecular cloning technology 
showed that several adrenoceptor subtypes exist. As Ahlquist stated, two main classes are 
known, ǂ- and ǃ-adrenoceptors. Each group is further subdivided so that five subtypes are 
presently recognized: two main ǂ-receptor subtypes (ǂ1 and ǂ2) and three ǃ-receptor 
subtypes (ǃ1, ǃ2 and ǃ3) (Alexander et al., 2008). The ǂ-receptor subtypes are nowadays 
accepted to be six subtypes in total (ǂ1A, ǂ1B, ǂ1D, ǂ2A/D, ǂ2B, ǂ2C). Other two adrenoceptors 
candidates were described (ǂ1L and ǃ4), that may be conformational states of ǂ1A and ǃ1-
adrenoceptors, respectively (Guimarães and Moura, 2001, Alexander et al., 2008) .  
The pharmacological actions of NA and ADR have been extensively compared in vivo and in 
vitro. Both drugs are direct agonists on effectors cells and their actions differ mainly in their 
ability to stimulate ǂ- and ǃ-receptors. ADR and NA are approximately equipotent in 
stimulating ǃ1-receptors. NA is a potent ǂ-agonist and has relatively little action on ǃ1-
receptors; however, NA is somewhat less potent than ADR on ǂ receptors in most organs 
(Westfall and Westfall, 2006). The rank order of potency is isoproterenol > ADR > NA for ǃ-
adrenergic receptors and ADR > NA >> isoproterenol for ǂ-adrenergic receptors 
(Guimarães, 1975, Westfall and Westfall, 2006, Rang et al., 2007).  
In the present review, the classical pharmacological point of view will be approached as it 
was historically the starting point in the study of the neurotransmission of catecholamines. 
Although not excluding neurotransmission plasticity and adaptation as key factors for the 
full understanding of the topic, these issues are still under debate, so they will not be 
addressed here. 
The knowledge of the characteristics of adrenergic receptors and the biochemical and 
physiological pathways that they regulate increased the understanding of the seemingly 
contradictory and variable effects of catecholamines on different organs. Although 
structurally related, different receptors regulate distinct physiological processes by 
controlling the synthesis or release of a variety of second messengers. The adrenoceptors are 
coupled to second-messenger systems via G proteins. The responses that follow the 
activation of adrenergic receptors result from G protein-mediated effects with the 
generation of second messengers and/or the activation of ion channels (Guimarães and 
Moura, 2001) (Figure 3). 
10.2 Alpha (α)-adrenoceptors 
ǂ1-Adrenoceptors are found in the smooth muscle of the blood vessels, bronchi, 
gastrointestinal tract, uterus, and bladder. The activation of these receptors is mainly 
excitatory and results in the contraction of smooth muscle. However, the smooth muscle of 
the gut wall (but not that of the sphincters) becomes relaxed after activation of ǂ1-receptors. 
Overall, the ǂ1-adrenoceptors cause vasoconstriction, relaxation of gastrointestinal smooth 
muscle, salivary secretion, and hepatic glycogenolysis (Pocock and Richards, 2006, Rang et 
al., 2007). ǂ1-Adrenoceptors are mainly coupled to Gq/11-protein with consequent activation 
of phospholipase C. Phospholipase C promotes the hydrolysis of phosphatidylinositol 
bisphosphate producing inositol trisphosphate and diacylglycerol (Docherty, 1998, Zhong 
and Minneman, 1999, García-Sáinz et al., 2000, Guimarães and Moura, 2001), which act as 
second messengers. Inositol trisphosphate mediates intracellular Ca2+ release from non 
mitochondrial pools and, consequently, the activation of other Ca2+ and calmodulin 
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sensitive pathways such as CaMKII, whilst diacylglycerol activates PKC (Guimarães and 
Moura, 2001, Westfall and Westfall, 2006). The three cloned ǂ1-adrenoceptor subtypes have 
significant differences in G protein coupling efficiency (ǂ1A > ǂ1B > ǂ1D) (Docherty, 1998, 
Zhong and Minneman, 1999, Guimarães and Moura, 2001).  
Other signalling pathways are also activated by ǂ1-adrenoceptors, namely: stimulation of 
phospholipase A2 leading to the release of free arachidonate, which is degraded by 
cyclooxygenase and lipoxygenase to form the bioactive prostaglandins and leukotrienes; 
Ca2+ influx via protein G; and phospholipase D activation (Docherty, 1998, Zhong and 
Minneman, 1999, Guimarães and Moura, 2001, Westfall and Westfall, 2006). Some of the 
responses induced by ǂ1-adrenoceptors are independent of Ca2+ and PKC but involve small 
G proteins and tyrosine kinases (Zhong and Minneman, 1999). Furthermore, ǂ1-
adrenoceptors are able to activate mitogen-activated protein kinase pathways in many cells 
(Della Rocca et al., 1997). The mitogen-activated protein kinase superfamily, which consists 
of extracellular signal-regulated kinases 1/2 and three stress-responsive subfamilies, the c-
Jun NH2-terminal kinases, p38-mitogen-activated protein kinase (p38-MAPK), and 
extracellular signal-regulated kinases, is normally stimulated by growth factors and cellular 
stress or inflammatory cytokines (Zhang et al., 2005).  
ǂ2-Adrenoceptors when located presynaptically are responsible for the inhibition of 
transmitter release (including NA and acetylcholine from autonomic nerves) and are 
considered modulators of neurotransmission (autoreceptors). The different ǂ2-receptors 
couple to a variety of effectors (Aantaa et al., 1995, Guimarães and Moura, 2001) and share 
about 50% in amino acid sequence in important domains (Aantaa et al., 1995). The 
importance of these receptors was well demonstrated in knockout mice for ǂ2-adrenoceptors 
(Vieira-Coelho et al., 2009). Brain tissue levels of L-3,4-dihydroxyphenylalanine, dopamine, 
and NA were significantly higher in the knockout mice for ǂ2A- and ǂ2C-adrenoceptors when 
compared to wild type. The activity of COMT was higher in all three knockout (ǂ2A-, ǂ2B- 
and ǂ2C-adrenoceptors), while the activities of MAO, dopamine ǃ-hydroxylase or tyrosine 
hydroxylase were unchanged (Vieira-Coelho et al., 2009). 
ǂ2-Adrenoceptors are predominantly coupled to the inhibitory G proteins, Gi and G(o), 
inhibiting the activity of adenylyl cyclase (Rouot et al., 1987, Cotecchia et al., 1990, 
Surprenant et al., 1992, Aantaa et al., 1995, Wise et al., 1997). The ǂ2-adrenoceptor 
stimulation leads to the activation of Na+/H+ exchange (Limbird, 1988), inhibition of the 
opening of voltage-gated Ca2+ channels (Cotecchia et al., 1990) or activation of K+ channels 
(Surprenant et al., 1992), all resulting in membrane hyperpolarization.  
ǂ2-Adrenoceptors are also found at postjunctional or nonjunctional sites in several tissues, 
thus their activation may also lead to the activation of other intracellular pathways. In 
peripheral tissues, postsynaptic ǂ2-receptors are found in vascular and other smooth muscle 
cells, in adipocytes, and in many types of secretory epithelial cells (intestinal, renal, and 
endocrine). The activation of ǂ2-adrenoceptors causes platelet aggregation, contraction of 
vascular smooth muscle, and inhibition of insulin release (Aantaa et al., 1995, Pocock and 
Richards, 2006, Rang et al., 2007). Intracellular pathways of postjunctional ǂ2-receptors are 
varied, with activation of phospholipase A2, C, and D, with arachidonic acid mobilization, 
increase in phosphoinositide hydrolysis, and increase in the intracellular availability of Ca2+ 
(Limbird, 1988, Cotecchia et al., 1990, MacNulty et al., 1992, Kukkonen et al., 1998). In 
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addition, ǂ2-adrenoceptors can activate mitogen-activated protein kinases (Della Rocca et al., 
1997, Richman and Regan, 1998).  
10.3 Beta (β)-adrenoceptors 
The three ǃ-adrenoceptor subtypes are encoded by three different genes located in human 
chromosomes 10 (ǃ1), 5 (ǃ2), and 8 (ǃ3). Approximately 60% of the amino acid sequence in 
membrane-spanning domains is the ligand-binding pocket for ADR and NA (Kobilka et al., 
1987, Emorine et al., 1989, Guimarães and Moura, 2001). 
ǃ1-Adrenoceptors are found in the heart where their activation results in increased rate and 
force of contraction. They are also present in the sphincter muscle of the gut where their 
activation leads to relaxation (Pocock and Richards, 2006, Westfall and Westfall, 2006, Rang 
et al., 2007). 
The activation of ǃ2-adrenoceptors in the smooth muscle of certain blood vessels leads to 
vasodilatation. They are also present in the bronchial smooth muscle where they mediate 
bronchodilatation. Relaxation of visceral smooth muscle, hepatic glycogenolysis, and muscle 
tremor occur after ǃ2-adrenoceptors activation. Postsynaptic ǃ2-receptors can be found in the 
myocardium, as well as on vascular and some smooth muscle cells (Gauthier et al., 1996, 
Gauthier et al., 2000, Pocock and Richards, 2006, Rang et al., 2007). The stimulation of 
prejunctional ǃ2-adrenoceptors leads to NA release in neurons (Boehm and Kubista, 2002). 
ǃ3-Adrenoceptors are present in adipose tissue, where they initiate lipolysis in white 
adipose tissue (Pocock and Richards, 2006, Rang et al., 2007). They are involved in the 
thermogenesis process that takes place in brown adipose tissue (Gauthier et al., 1996). ǃ3-
Adrenoceptors are also present in the heart although their functions are not fully 
understood (Gauthier et al., 1996, Gauthier et al., 2000). 
All ǃ-receptor subtypes (ǃ1, ǃ2, and ǃ3) are coupled to the stimulatory G protein (Gs) leading 
to the activation of adenylyl cyclase and accumulation of the second messenger, cyclic 
adenosine monophosphate (cAMP) (Frielle et al., 1987, Emorine et al., 1989, Brown, 1990, 
Westfall and Westfall, 2006). Accumulation of cAMP leads to PKA activation with 
phosphorylation of several proteins, whose functions are changed as a result. 
Curiously, several works indicate that, under certain circumstances, ǃ-adrenoceptors can 
couple to Gi in addition to Gs. In fact, ǃ3-receptors interact with both Gs and Gi, whereas ǃ1-
receptors couple predominantly to Gs (Asano et al., 1984, Chaudhry et al., 1994, Gauthier et 
al., 1996). ǃ2-Receptors usually bind to Gs but, after sustained activation, they couple to Gi 
(Xiao et al., 1995, Lefkowitz et al., 2002). 
10.4 Location and regulation of adrenoceptors 
The adrenoceptors are targets for many important drugs in therapeutics, including those 
used for treatment of cardiovascular diseases, asthma, prostatic hypertrophy, nasal 
congestion, obesity, and pain (Guimarães and Moura, 2001, Pocock and Richards, 2006). 
From a therapeutic standpoint, there are many occasions where the ǃ-adrenoceptor 
selective stimulation (asthma, atrioventricular block, obesity) or blockage (hypertension, 
coronary insufficiency) is desired. ǂ2-Agonists are used in hypertension and ǂ1-agonist in 
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nasal congestion (Aantaa et al., 1995, Guimarães and Moura, 2001, Westfall and Westfall, 
2006, Rang et al., 2007). Inhibition of ǂ1-adrenoceptors has also proven useful to treat 
hypertension and prostate hypertrophy (Zhong and Minneman, 1999, Westfall and 
Westfall, 2006).  
The ǂ- and ǃ-receptors appear to be located pre- and postsynaptically. The ǂ1- and ǃ1-
receptors are mainly in the vicinity of sympathetic adrenergic nerve terminals in peripheral 
target organs, or distributed in the mammalian brain (Westfall and Westfall, 2006). The ǂ2- 
and ǃ2-receptors are heterogeneously distributed. Both ǂ2- and ǃ2-receptors may be situated 
at sites (vascular smooth muscle, platelets and leukocytes) that are relatively remote from 
nerve terminals and may be activated preferentially by circulating catecholamines (in 
particular ADR) (Westfall and Westfall, 2006). On the other hand, presynaptically located 
ǂ2- and ǃ2-adrenoceptors have important roles in the modulation of neurotransmitter release 
from sympathetic nerve endings (Figure 3). 
Responses mediated by adrenoceptors are not static, as they can be modulated and adjusted. 
The number and function of adrenoceptors on the cell’s surface and their elicited responses 
may be altered by catecholamines themselves, by other hormones and drugs but they can also 
change with age and disease. The release of neurotransmitters can be modulated by 
prejunctional autoreceptors. NA or ADR, neuropeptide Y, and ATP (the last two are frequent 
cotransmitters in the adrenergic transmission) elicit a feedback response on prejunctional 
receptors (Boehm and Kubista, 2002, Westfall et al., 2002). The most studied autoreceptors 
have been the prejunctional ǂ2-adrenergic receptors (Aantaa et al., 1995). The ǂ2A- (ǂ2D-, 
depending on the species investigated) and ǂ2C-adrenergic receptors are the principal 
prejunctional receptors that inhibit sympathetic neurotransmitter release, whereas the ǂ2B-
adrenergic receptors may also inhibit the release of transmitters at selected sites (Boehm and 
Kubista, 2002). Antagonists of these receptors, in turn, can enhance the electrically evoked 
release of sympathetic neurotransmitters. Neuropeptide Y, acting on Y2 receptors (Chen et al., 
1997), and ATP-derived adenosine, acting on P1 (A1) receptors, can also inhibit sympathetic 
neurotransmitter release, while nucleotides, acting on P2 receptors have inhibitory or 
facilitator effects, depending on the tissue evaluated (Driessen et al., 1994, Boehm and Kubista, 
2002, Hoffmann, 2004). Other heteroreceptors present in sympathetic nerve varicosities can 
likewise inhibit the release of sympathetic neurotransmitters, namely through the activation of 
M2 and M4 muscarinic, 5-HT, prostaglandin E2, histamine, enkephalin, and dopamine 
receptors (Lefkowitz et al., 1990, Gainetdinov et al., 2004, Hata et al., 2004).  
Enhancement of sympathetic neurotransmitter release can occur after the activation of 
presynaptic ǃ2-adrenergic, angiotensin II, and nicotinic receptors. All of these receptors can 
be targets for agonists and antagonists (Boehm and Kubista, 2002). 
The modulation of synaptic transmission is a crucial step in homeostasis, where receptors 
have key roles. The continuous exposure to adrenergic agonists causes a progressive 
decrease in the capacity to respond to those agents by catecholamine-sensitive cells. This 
phenomenon, often termed refractoriness, or desensitization, is another “check point” in 
neuroendrocrine regulation (García-Sáinz et al., 2000, Hoffmann, 2004). Two major types of 
desensitization have been distinguished: homologous and heterologous. In the homologous, 
reduced responsiveness is observed exclusively in the receptor originally stimulated. In 
heterologous desensitization, a decreased responsiveness is observed to an agent or agents 
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unrelated to the initial stimulus. Certainly, this classification is only operational and both 
types of desensitization may occur simultaneously in the cells (García-Sáinz et al., 2000). 
Even so, the mechanisms are equally complex and need further characterization. 
ǃ-Adrenoceptor feedback regulation is common; however, ǃ-receptors differ in the extent to 
which they can undergo such regulation, with the ǃ2-receptors being the most susceptible. 
Upon challenge with an agonist, the ǃ2-receptor couples to Gs and activates adenylyl cyclase 
to form cAMP. cAMP leads to stimulation of cyclic AMP-dependent protein kinases, like 
PKA, with consequent phosphorylation of ǃ-receptor. That phosphorylation provides the 
signal for ǃ-arrestin recruitment. Arrestins constitute a large family of widely expressed 
proteins (Baillie and Houslay, 2005, Westfall and Westfall, 2006). ǃ-arrestin translocation 
from the cytosol to the activated ǃ-receptor physically blocks the interaction of the receptor 
with its cellular effectors, presumably due to steric hindrance (Lefkowitz and Shenoy, 2005). 
The receptor phosphorylation followed by ǃ-arrestin binding has been linked to subsequent 
endocytosis of the receptor. The capacity of ǃ-arrestins to bind to the structural protein 
clathrin, initiating the internalization of phosphorylated receptors into vesicles, facilitates 
endocytosis (Goodman et al., 1996, Nelson et al., 2008). In addition to blunting responses 
that require the presence of the receptor on the surface of the cell, these regulatory processes 
may also contribute to novel mechanisms of receptor signalling via intracellular pathways 
(Baillie and Houslay, 2005). 
Receptor desensitization may also be mediated by second messenger feedback. For example, 
ǃ-adrenoceptor-mediated cAMP accumulation leads to activation of PKA, which can 
phosphorylate residues of ǃ-receptors, which results in their own inhibition. For the ǃ2-
receptor, phosphorylation occurs on serine residues both in the third cytoplasmic loop and 
in the carboxyl terminal tail of the receptor. ǃ3-Receptors do not suffer down regulation, 
since they lack recognition sites for the cAMP dependent kinases activated by stimulation of 
ǃ-adrenoceptors (Gauthier et al., 1996).  
Although less addressed, ǂ-receptors desensitization has gained increased interest (García- 
Sáinz et al., 2000). Current data indicate that the decrease in receptor activity is associated 
with a homologous desensitization mechanism. The activation of PKC by Gq-coupled 
receptors may lead to phosphorylation of this class of G protein-coupled receptors. That 
phosphorylation constitutes a very substantial sterical impediment for the effective 
interaction of receptors with G proteins. Receptor phosphorylation is associated with 
receptor internalization and ǃ-arrestins are involved (García- Sáinz et al., 2000).  
In the case of ǂ-receptors heterologous desensitization, it is not completely clear whether 
kinases, arrestins, or other molecules play the main role (García-Sáinz et al., 2000). However, 
activated PKA or PKC may phosphorylate any structurally similar receptor with the 
appropriate consensus sites for phosphorylation, a process which is considered a 
heterologous desensitization (Gainetdinov et al., 2004, Hoffmann, 2004).11. Summary 
The autonomic nervous system is considered responsible for organ specific adjustments to 
the environment, while the endocrine system regulates more generalized adaptations by 
releasing hormones into the systemic circulation that act on “distant places” (Westfall and 
Westfall, 2006). NA and ADR play crucial roles in the interaction between the autonomic 
and endocrine systems when the body has to adjust to several and varied situations. It is of 
outmost importance that their roles and all the participants in the “adrenergic” system are 
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well known. It is absolutely certain that, as it happened during the twentieth century, the 
new century will bring new and fascinating discoveries in this area that will challenge 
existing preconceptions. However, the knowledge gathered until this point resulted of the 
work of several notorious scientists whose work should not be forgotten but remembered 
and valued. 
11. Abbreviations 
Adrenaline; Epinephrine (ADR); Adenosine-5'-triphosphate (ATP); Adenosine 
triphosphatase (ATPase); Calcium ion (Ca2+); Ca2+/calmodulin-dependent protein kinase II 
(CaMKII); Cyclic adenosine monophosphate (cAMP); Catechol-O-methyltransferase 
(COMT); Dihydroxyphenylglycol (DHPG); Deoxyribonucleic acid (DNA); Inhibitory G 
protein (Gi); Stimulatory G protein (Gs); 5-Hydroxytriptamine; Serotonin (5-HT); 
Homovanillic acid (HVA); Potassium ion (K+); Half-saturation constant; Michaelis constant 
(Km); Monoamine oxidase (MAO); Magnesium ion (Mg2+); Sodium ion (Na+); 
Noradrenaline; Norepinephrine (NA); Noradrenaline transporter (NET); Superoxide anion 
(O2●–); Organic cation transporters (OCT); Hydroxyl radical (HO●); Phenylethanolamine N-
methyltransferase; Noradrenaline N-methyltransferase (PMNT); Ribonucleic acid (RNA); 
Vanillylmandelic acid; Methoxy-4-hydroxymandelic acid (VMA); Vesicular monoamine 
transporter (VMAT). 
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including the pathways followed by cells, how individuals communicate with each other, inflammation, learning
and memory, the development of drug dependence, and approaches to explaining the processes that underlie
two highly incapacitating chronic degenerative illnesses.
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